2nd Quarter 2020 Results

2nd Quarter 2020 Sales

Worldwide Decreased 18.3B (10.8\%)
Excluding acquisitions/ divestitures on an operational basis

Diluted Earnings Per Share Decreased $1.36 (34.6\%)
Adjusted Diluted Earnings Per Share Decreased $1.67 (35.3\%)

“Our second quarter results reflect the impact of COVID-19 and the enduring strength of our Pharmaceutical business, where we saw continued growth even in this environment. Thanks to the tireless work of our colleagues around the world and our broad range of capabilities, we continue to successfully navigate the external landscape, and we remain focused on advancing the development of a vaccine to help address this pandemic and save lives. We are bringing together our best minds, our global footprint and our sophisticated supply chain technology to deliver on our commitment to provide the vaccine on a not-for-profit basis for emergency pandemic use, globally. We know the need is urgent, and every day we commit to doing our part to find a solution for the good world.”

$3.3 Billion
Worldwide Consumer Health Sales
Consumer Health worldwide reported sales decreased (7.0\%) or (3.6\%) operationally. Primary offsets to decline:

$10.8 Billion
Worldwide Pharmaceutical Sales
Pharmaceutical worldwide reported sales increased 2.1\% or 3.9\% operationally. Primary operational drivers:

$4.3 Billion
Worldwide Medical Devices Sales
Medical Devices worldwide reported sales decreased (33.9\%) or (32.7\%) operationally. Primary operational drivers:

Note: values may have been rounded


*Non-GAAP financial measures: Non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.

Non-GAAP measures exclude the impact of transitional currency.


For important information about the risks and uncertainties that could cause actual results to vary materially, see the cautionary forward-looking statements in Johnson & Johnson’s earnings release issued on July 16, 2020, as well as the most recently filed Johnson & Johnson Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q.